Introduction
============

Atrial fibrillation (AF)---the most common arrhythmia---affects 6 million individuals in the United States. AF is associated with an increased risk of stroke^[@b1]--[@b2]^ that can be fatal, and survivors are often left permanently disabled. Mechanistically, cerebrovascular events in AF patients are thought to result from ineffective contraction during AF and subsequent intracardiac thrombosis. However, recent evidence suggests that underlying atrial fibrosis and subsequent atrial dysfunction may also be mechanistically contributing to cerebrovascular events in AF patients. For example, an increased left atrial (LA) volume and global LA dysfunction in *individuals without clinically recognized AF* are an independent predictor of clinical stroke/transient ischemic attack (TIA)^[@b3]--[@b4]^ as well as subclinical cerebrovascular events detected by brain magnetic resonance imaging (MRI).^[@b5]^ Our previous study demonstrated that the degree of regional LA dysfunction *during sinus rhythm* is proportional to the extent of underlying fibrosis quantified by late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) in AF patients.^[@b6]^ In addition, regional LA function *during AF* is significantly depressed in patients with a prior history of stroke compared with those without, independent of the CHA~2~DS~2~‐VASc score,^[@b7]--[@b8]^ the standard system of risk stratification for stroke based on age, sex, and comorbidities.^[@b9]^

To further support the concept that the underlying atrial fibrosis and subsequent LA dysfunction may be mechanistically contributing to cerebrovascular events in AF patients, we investigated the association between regional LA function and a prior history of stroke *during sinus rhythm* in patients referred for catheter ablation of AF. We used tissue‐tracking CMR^[@b10]--[@b11]^ to quantify the LA volume and regional LA function.

Methods
=======

Study Design
------------

To examine the association of LA structure and function as determined by tissue‐tracking CMR with a prior history of stroke or TIA, a single‐center, retrospective, cross‐sectional study was performed within a longitudinal, prospectively enrolled database for all the patients referred to the Johns Hopkins Hospital for catheter ablation of AF. Between June 2010 and August 2013, 525 consecutive patients were referred for AF ablation ([Figure 1](#fig01){ref-type="fig"}). Among these, 300 patients underwent a routine pre‐ablation CMR. We excluded patients who were in AF at the time of CMR (n=92, 31%) because the CMR image quality is often poor and the measured LA strains are depressed during AF compared with those in sinus rhythm.^[@b12]^ We also excluded patients who had a prior AF ablation procedure (n=33), severe valvular disease in echocardiography (n=3), or poor‐quality CMR images (n=3). Thus, 169 patients were included in the final analysis. The stroke group (n=18, 11.8%) was identified as those with a prior history of stroke or TIA at the time of CMR; the remaining patients were designated as the control group (n=151). The patients were classified as having either paroxysmal or persistent AF based on the guidelines,^[@b9]^ and the thromboembolic risk was assessed using the CHADS~2~ and the CHA~2~DS~2~‐VASc scores.^[@b13]--[@b14]^ In general, the patients with persistent AF were placed on antiarrhythmic medications and referred for external cardioversion 3 to 4 weeks prior to CMR.^[@b15]^ All patients gave an informed consent to be included in the prospective patient database prior to the pre‐ablation CMR, and the protocol was approved by the Institutional Review Board of the Johns Hopkins Medicine.

![Patient enrollment. AF indicates atrial fibrillation; CMR, cardiac magnetic resonance.](jah3-4-e001844-g1){#fig01}

CMR Protocol
------------

CMR was performed with a 1.5‐T scanner (Avanto; Siemens Medical Systems, Erlangen, Germany) and a 6‐channel phased array body coil in combination with a 6‐channel spine matrix coil. All images were ECG gated and acquired with breath‐holding, with the patient in a supine position. Cine CMR images were scanned in the radial long axis by True Fast Imaging with Steady‐State Precession (TrueFISP) sequence with a TE/TR and flip angle of 1.2/2.4 ms and 80°, an in‐plane resolution of 1.4×1.4 mm, a slice thickness of 8 mm, and a spacing of 2 mm. The images were acquired with 30 frames during the time interval between the R‐peak of the ECG (temporal resolution, 20 to 40 ms). Among the 169 patients included in the final analysis, 85 (n=5 in the stroke group and n=80 in control group) also underwent late gadolinium enhancement (LGE) to quantify LA fibrosis. LGE‐MRI scans were acquired within a range of 15 to 25 minutes after the injection of gadopentetate dimeglumine (0.2 mmol/kg, Bayer Healthcare Pharmaceuticals, Montville, NJ) using a fat‐saturated 3‐dimensional (3‐D) inversion recovery‐prepared fast spoiled gradient‐recalled echo sequence with the following: respiratory navigation and ECG gating with TE/TR and flip angle of 1.52/3.8 ms and 10°, an in‐plane resolution of 1.3×1.3 mm, and a slice thickness of 2.0 mm. Trigger time for 3‐DLGE‐MRI images was optimized to acquire imaging data during diastole of LA as observed from the cine images. The optimal inversion time was identified with an inversion time scout scan (median 270 ms; range 240 to 290 ms) to maximize nulling of the LA myocardium. A parallel imaging technique---generalized autocalibrating partially parallel acquisition (reduction factor 2)---was used. Image processing was conducted in QMass MR (version 7.2; Leiden University Medical Center, Leiden, The Netherlands) on multiplanar reformatted axial images from 3‐D axial image data. To define LA fibrosis, we used the cutoff value of \>0.97 for image intensity ratio, which has been shown to correspond to the bipolar voltage \<0.5 mV.^[@b16]^

Tissue‐Tracking CMR
-------------------

We used off‐line semiautomated multimodality tissue‐tracking software version 6.0 (Toshiba, Tokyo, Japan) to analyze the LA and left ventricular (LV) structure and function in long‐axis 2‐ and 4‐chamber cine images ([Figure 2](#fig02){ref-type="fig"}A and [2](#fig02){ref-type="fig"}B).^[@b1]^ The endo‐ and epicardial borders, excluding pulmonary veins and LA appendage, were manually traced. The number of pixels that lay across the LA and LV wall was 2.2±1.2 and 8.8±2.7, respectively. Multimodality tissue‐tracking is similar in concept to 2‐dimensional (2‐D) speckle‐tracking imaging. Briefly, multimodality tissue‐tracking reads characteristic pixel patterns in each 10×10 mm area as template pieces from the reference image. The identified area as a template was searched in the next frame to find the best match according to the mean squared error of the image pixel intensity. This was used to accurately track pixel locations between subsequent image frames. Repeating the algorithm, the LA wall was automatically tracked through the cardiac cycle (Videos S1 and S2). With this 2‐D displacement field over time from the reference configuration to the deformed configuration, the differentiation with respect to the reference configuration gives the deformation gradient tensor (**F**), which depends on position. The Lagrangian Green\'s strain tensor (**E**) was then calculated as:where **F**^T^ is the transpose of **F** and **I** is the identity matrix. The strain (S) was defined as a stretch ratio along the longitudinal axis that represents the length normalized to its length at the reference configuration:where E~ll~ is the strain with respect to the local longitudinal axis calculated from the **E.**

![LA measurements by tissue‐tracking CMR in a patient without stroke. A and B, Left atrium (LA) longitudinal strain in the 2‐ and 4‐chamber views at the end of left ventricular (LV) systole. C, LA volume curve. The pink dotted line is the average of the values of volume in the 2‐ and 4‐chamber views. The LA maximum volume (V~max~), the pre‐atrial contraction volume (V~preA~), and the minimum volume (V~min~) were identified. The LA emptying fractions (EFs) were calculated using V~max~, V~preA~, and V~min~. D and E, The LA strain and strain rate curve. The LA maximum strain (S~max~) and pre‐atrial contraction strain (S~preA~) were identified from the strain curve. The strain rates during LV systole (SR~s~), LV early diastole (SR~e~), and atrial contraction (SR~a~) were also analyzed from the strain rate curve. CMR indicates cardiac magnetic resonance.](jah3-4-e001844-g2){#fig02}

The global longitudinal strain and strain rate were calculated by averaging all of the strain values obtained in long‐axis 2‐ and 4‐chamber views. A positive and negative strain value indicates stretch and shortening, respectively, with respect to the reference configuration at the ventricular end‐diastole defined as the peak of R wave on surface ECG. LA maximum strain (S~max~) and pre‐atrial contraction strain (S~preA~) were identified from the strain curve ([Figure 2](#fig02){ref-type="fig"}D); the strain rates in LV systole (SR~s~), LV early diastole (SR~e~), and LA contraction (SR~a~) were obtained from the strain rate curve ([Figure 2](#fig02){ref-type="fig"}E).

The LA volume curve was generated by the biplane modified Simpson\'s method, which was validated using the area‐length method,^[@b17],[@b10],[@b18]^ and the maximum LA volume (V~max~), pre‐atrial contraction LA volume (V~preA~), and minimum LA volume (V~min~) were extracted ([Figure 2](#fig02){ref-type="fig"}C). All the LA volumes were indexed by the body surface area (BSA) according to DuBois' formula (eg, BSA=0.007184×\[weight^0.425^\]×\[height^0.725^\]). From the LA volumes, the LA emptying fractions (EF) were calculated as follows^[@b19]^: (1) LA total EF=(V~max~−V~min~)×100%/V~max~, (2) LA passive EF=(V~max~−V~preA~)×100%/V~max~, and (3) LA active EF=(V~preA~−V~min~)×100%/V~preA~.

Reproducibility
---------------

Intra‐ and interobserver reproducibility for the LA parameters were examined in a group of 20 randomly selected patients by 1 investigator who made 2 independent measurements, and by 2 other investigators who were unaware of the other investigator\'s measurements and of the study time point. The bias (mean difference) and limits of agreement (1.96 SD of difference) between the first and second measurements were determined by the Bland‐Altman method. Intraclass correlation coefficients were also assessed to evaluate reproducibility.

Statistical Analysis
--------------------

Continuous variables were presented as the means±SD and categorical variables as frequencies and percentages. The participants' baseline data and LA parameters were compared between the stroke and the control groups using Student *t* test for continuous variables and χ^2^ test for categorical variables. Univariable and multivariable logistic regression analyses were performed to evaluate the association between clinical variables and stroke/TIA. Model 1 reflected (univariable) unadjusted relations of LA and LV measurements to stroke/TIA. Model 2 was adjusted for the CHA~2~DS~2~‐VASc score prior to stroke/TIA to incorporate a history of Cardiac failure, Hypertension, Age, Diabetes, Stroke/TIA, Vascular disease, and Sex. In Model 3, an additional adjustment was made for the LA V~min~. The incremental value for assessing the risk of stroke was studied by calculating the improvement in the global χ^2^. Data were analyzed with JMP version 10.0 (SAS Institute, Inc, Cary, NC) and MedCalc version 13.3 (MedCalc Software, Inc, Mariakerke, Belgium). A 2‐sided *P*‐value of \<0.05 was considered statistically significant.

Results
=======

Patient Demographics
--------------------

Clinical characteristics of the patients are summarized in [Table 1](#tbl01){ref-type="table"}. A total of 169 patients (59±10 years, 74% male, 29% persistent AF) were included in the analysis. Compared to the control group, patients in the stroke group were significantly older (*P*=0.02). Other clinical characteristics, including the CHADS~2~ score and CHA~2~DS~2~‐VASc scores, did not show any significant difference between the stroke and control groups. Three of 18 patients (16.7%) in the stroke group and 18 of 151 patients (11.9%) in the control group underwent cardioversion before pre‐ablation CMR (*P*=0.84). There was no significant difference in AF duration before cardioversion (3.3±3.2 versus 1.2±1.3 years, *P*=0.15) and the time from cardioversion to CMR (59.7±42.7 versus 52.2±42.7 days, *P*=0.80).

###### 

Patient Demographics

                                         Stroke (n=18)   Control (n=151)   *P* Value
  -------------------------------------- --------------- ----------------- ---------------------------------------
  Age, y                                 65.0±8.2        58.5±10.6         0.02[\*](#tf1-1){ref-type="table-fn"}
  Sex, male                              12 (66.7)       113 (74.8)        0.50
  Body mass index, kg/m^2^               27.8±2.4        28.0±5.3          0.94
  Type of AF (persistent)                5 (27.8)        44 (29.1)         0.91
  Coronary artery disease                4 (22.2)        16 (10.6)         0.14
  Hypertension                           7 (38.9)        60 (39.7)         0.94
  Heart failure                          2 (11.1)        12 (7.9)          0.63
  Diabetes mellitus                      3 (16.7)        18 (11.9)         0.55
  CHADS~2~ score before stroke           0.94±0.90       0.74±0.90         0.20
  CHA~2~DS~2~‐VASc score before stroke   2.00±1.32       1.45±1.49         0.07
  Medications                                                              
  β‐Blockers                             10 (55.5)       73 (48.3)         0.70
  Ca‐channel blockers                    6 (33.3)        33 (21.9)         0.44
  ACE inhibitors/ARBs                    6 (33.3)        49 (32.5)         0.96
  Statins                                7 (38.9)        62 (41.1)         0.86
  Number of antiarrhythmic drugs         1.4±0.9         1.6±0.9           0.60

Data are expressed as the means±SD, or as n (%). ACE indicates angiotensin‐converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker.

*P*\<0.05.

LA Function and Stroke
----------------------

The time course of LA volume, strain, and strain rate in representative patients with and without stroke are shown in [Figure 3](#fig03){ref-type="fig"}. The CMR parameters in the stroke and the control groups are shown in [Table 2](#tbl02){ref-type="table"}. In the stroke group, the LA volumes (V~max~, V~preA~, and V~min~) were significantly higher, the LA EFs (total, passive, and active) were lower, the LA longitudinal S~max~ and S~preA~ were lower, and the absolute values of the LA SR~s~ and SR~e~ were lower than in the control group. There was no significant difference regarding LA wall LGE between the 2 groups (stroke group versus control group: 29.3±17.6% versus 27.1±16.1%, respectively, *P*=0.75). LV parameters, including mass index, ejection fraction, end‐diastolic volume index, and longitudinal strain, did not show any significant difference between the stroke and control groups.

###### 

Comparison of CMR Measurements Between the Stroke and Control Groups

                                           Stroke (n=18)   Control (n=151)   *P* Value
  ---------------------------------------- --------------- ----------------- ------------------------------------------
  LA V~max~, mL/m^2^                       52.2±16.2       44.2±12.9         0.024[\*](#tf2-1){ref-type="table-fn"}
  LA V~preA~, mL/m^2^                      44.8±14.5       35.7±11.7         0.005[\*](#tf2-1){ref-type="table-fn"}
  LA V~min~, mL/m^2^                       35.1±15.8       24.6±10.7         \<0.001[\*](#tf2-1){ref-type="table-fn"}
  LA total EF, %                           34.6±13.5       45.6±11.8         \<0.001[\*](#tf2-1){ref-type="table-fn"}
  LA passive EF, %                         14.1±5.6        19.7±7.8          0.005[\*](#tf2-1){ref-type="table-fn"}
  LA active EF, %                          23.8±15.8       32.7±10.9         0.004[\*](#tf2-1){ref-type="table-fn"}
  LA S~max~, %                             19.4±9.2        28.6±10.6         \<0.001[\*](#tf2-1){ref-type="table-fn"}
  LA S~preA~, %                            10.1±6.6        15.0±7.1          0.010[\*](#tf2-1){ref-type="table-fn"}
  LA SR~s~, 1/s                            0.81±0.37       1.15±0.47         0.005[\*](#tf2-1){ref-type="table-fn"}
  LA SR~e~, 1/s                            −0.78±0.41      −1.12±0.62        0.033[\*](#tf2-1){ref-type="table-fn"}
  LA SR~a~, 1/s                            −1.14±0.55      −1.52±0.84        0.071
  LV mass index, g/m^2^                    71.0±16.1       65.6±14.6         0.177
  LV ejection fraction, %                  54.4±14.6       57.3±9.5          0.281
  LV end‐diastolic volume index, mL/m^2^   78.7±26.7       71.7±12.4         0.292
  LV longitudinal strain, %                −16.5±5.2       −18.2±4.4         0.149

Data are expressed as the means±SD. CMR indicates cardiac magnetic resonance; EF, emptying fraction; LA, left atrial; LV, left ventricular; S~max~, maximum strain; S~preA~, pre‐atrial contraction strain; SR~a~, strain rate at atrial contraction; SR~e~, strain rate at LV early diastole; SR~s~, maximum strain rate; V~max~, maximum indexed volume; V~min~, minimum indexed volume; V~preA~, pre‐atrial contraction indexed volume.

*P*\<0.05.

![LA measurements by tissue‐tracking CMR in patients with and without stroke. A, The LA volume, (B) LA global longitudinal strain, and (C) LA strain rate in a patient with stroke (red line) and without stroke (blue line). The patient with stroke has a larger LA volume and smaller strain and strain rate. The LA serves as a reservoir during LV systole, as a conduit during LV early diastole, and as an active pump during late diastole. CMR indicates cardiac magnetic resonance; LA, left atrial; LV, left ventricular; S~max~, maximum strain; S~preA~, pre‐atrial contraction strain; SR~a~, strain rate at atrial contraction; SR~e~, strain rate at LV early diastole; SR~s~, maximum strain rate; V~max~, maximum indexed volume; V~min~, minimum indexed volume; V~preA~, pre‐atrial contraction indexed volume.](jah3-4-e001844-g3){#fig03}

Univariable and Multivariable Analyses
--------------------------------------

The univariable and multivariable analyses regarding the association between the CMR‐measured parameters and stroke are summarized in [Table 3](#tbl03){ref-type="table"}. In Model 1, a univariable analysis identified larger LA volumes (V~max~, V~preA~, and V~min~), lower EFs (total, active, and passive EF), lower strains (S~max~ and S~preA~), and lower absolute values of SR (SR~s~ and SR~e~) as significant contributors to stroke, indicating that all of the LA parameters that differed significantly between the stroke and control groups in [Table 2](#tbl02){ref-type="table"} remained significant and were associated with stroke. In Model 2, larger V~preA~ and V~min~, lower EFs (total, active, and passive EF), lower strains (S~max~ and S~preA~), and lower SR~s~ were significantly associated with stroke after adjusting for the CHA~2~DS~2~‐VASc score. In Model 3, only the LA total EF, S~max~, and SR~s~, which reflect the LA reservoir function (Figures [2](#fig02){ref-type="fig"} and [3](#fig03){ref-type="fig"}), remained significant after additionally adjusting for the LA V~min~.

###### 

Univariable and Multivariable Analyses of the Associations Between CMR Measurements and Stroke

                           Model 1   Model 2        Model 3                                                                                                                       
  ------------------------ --------- -------------- ---------------------------------------- ------ -------------- ---------------------------------------- ------ -------------- ----------------------------------------
  LA V~max~                1.04      1.01 to 1.08   0.030[\*](#tf3-1){ref-type="table-fn"}   1.04   0.99 to 1.08   0.062                                    ---                   
  LA V~preA~               1.06      1.02 to 1.10   0.008[\*](#tf3-1){ref-type="table-fn"}   1.05   1.01 to 1.10   0.019[\*](#tf3-1){ref-type="table-fn"}   ---                   
  LA V~min~                1.07      1.03 to 1.11   0.002[\*](#tf3-1){ref-type="table-fn"}   1.06   1.02 to 1.11   0.005[\*](#tf3-1){ref-type="table-fn"}   ---                   
  LA total EF              0.93      0.89 to 0.97   0.002[\*](#tf3-1){ref-type="table-fn"}   0.93   0.89 to 0.97   0.002[\*](#tf3-1){ref-type="table-fn"}   0.94   0.89 to 0.99   0.030[\*](#tf3-1){ref-type="table-fn"}
  LA passive EF            0.89      0.81 to 0.96   0.007[\*](#tf3-1){ref-type="table-fn"}   0.89   0.81 to 0.96   0.020[\*](#tf3-1){ref-type="table-fn"}   0.92   0.83 to 1.00   0.063
  LA active EF             0.94      0.90 to 0.98   0.006[\*](#tf3-1){ref-type="table-fn"}   0.94   0.90 to 0.98   0.008[\*](#tf3-1){ref-type="table-fn"}   0.96   0.91 to 1.00   0.074
  LA S~max~                0.90      0.83 to 0.96   0.002[\*](#tf3-1){ref-type="table-fn"}   0.90   0.83 to 0.95   0.002[\*](#tf3-1){ref-type="table-fn"}   0.91   0.84 to 0.97   0.018[\*](#tf3-1){ref-type="table-fn"}
  LA S~preA~               0.89      0.80 to 0.97   0.012[\*](#tf3-1){ref-type="table-fn"}   0.89   0.80 to 0.97   0.016[\*](#tf3-1){ref-type="table-fn"}   0.92   0.82 to 1.01   0.091
  LA SR~s~                 0.10      0.02 to 0.44   0.006[\*](#tf3-1){ref-type="table-fn"}   0.11   0.02 to 0.50   0.009[\*](#tf3-1){ref-type="table-fn"}   0.17   0.02 to 0.94   0.042[\*](#tf3-1){ref-type="table-fn"}
  LA SR~e~                 3.11      1.14 to 8.72   0.039[\*](#tf3-1){ref-type="table-fn"}   2.88   1.04 to 9.69   0.055                                    2.21   0.72 to 7.49   0.175
  LA SR~a~                 2.21      1.02 to 5.50   0.066                                    2.08   0.94 to 5.24   0.095                                    1.48   0.66 to 3.94   0.391
  LV mass index            1.03      0.99 to 1.06   0.189                                    1.02   0.98 to 1.06   0.224                                    1.02   0.98 to 1.06   0.321
  LV ejection fraction     0.98      0.93 to 1.03   0.301                                    0.98   0.93 to 1.03   0.347                                    0.98   0.93 to 1.06   0.547
  LV EDVI                  1.02      0.99 to 1.05   0.253                                    0.98   0.95 to 1.01   0.262                                    0.98   0.95 to 1.01   0.303
  LV longitudinal strain   1.08      0.97 to 1.21   0.151                                    1.07   0.96 to 1.20   0.223                                    1.05   0.94 to 1.18   0.399

Model 1: unadjusted. Model 2: adjusted for CHA~2~DS~2~‐VASc score. Model 3: additionally adjusted for the LA V~min~. CMR indicates cardiac magnetic resonance; EDVI, end‐diastolic volume index; EF, emptying fraction; LA, left atrial; LV, left ventricular; OR, odds ratio; S~max~, maximum strain; S~preA~, pre‐atrial contraction strain; SR~a~, strain rate at atrial contraction; SR~e~, strain rate at LV early diastole; SR~s~, maximum strain rate; V~max~, maximum indexed volume; V~min~, minimum indexed volume; V~preA~, pre‐atrial contraction indexed volume.

*P*\<0.05.

Incremental Value of LA Function as a Marker of Stroke
------------------------------------------------------

Additionally, we found that adding the CMR‐measured LA function significantly improved the statistics of the model on the basis of the conventional risk stratification of strokes ([Figure 4](#fig04){ref-type="fig"}). The LA V~min~ provided incremental value over the CHA~2~DS~2~‐VASc score, and the diagnostic value was further improved by adding the global LA S~max~ (*P*=0.017 and 0.009, respectively).

![Incremental value of left atrial (LA) strain for diagnosis of stroke. The addition of the LA minimum volume (V~min~) to the model on the basis of the CHA~2~DS~2~‐VASc score resulted in significant improvement in the diagnostic value for stroke. The value was further increased by adding the LA global longitudinal maximum strain (S~max~).](jah3-4-e001844-g4){#fig04}

Reproducibility of LA Analysis by Tissue‐Tracking CMR
-----------------------------------------------------

The intra‐observer intraclass correlation coefficient was between 0.88 and 0.99, and the interobserver intraclass correlation coefficient was between 0.89 and 0.99 for all measured LA parameters from tissue‐tracking CMR ([Table 4](#tbl04){ref-type="table"}).

###### 

Reproducibility of the LA Analysis by Tissue‐Tracking CMR

                        Intra‐Observer   Inter‐Observer                         
  --------------------- ---------------- ---------------- ------ ------- ------ ------
  LA V~max~, mL/m^2^    −0.57            4.50             0.96   −1.25   4.08   0.99
  LA V~preA~, mL/m^2^   −0.93            3.42             0.97   −0.34   4.75   0.99
  LA V~min~, mL/m^2^    −0.83            3.68             0.98   −1.61   4.31   0.98
  LA total EF, %        1.94             7.75             0.94   1.67    4.78   0.89
  LA passive EF, %      0.82             5.41             0.98   −0.92   7.81   0.92
  LA active EF, %       2.47             10.78            0.88   3.11    0.51   0.90
  LA S~max~, %          −0.75            3.19             0.94   1.26    2.88   0.90
  LA S~preA~, %         −1.20            2.99             0.96   1.64    2.17   0.98
  LA SR~s~, 1/s         0.10             0.43             0.91   0.11    0.18   0.95
  LA SR~e~, 1/s         −0.04            0.24             0.98   −0.15   0.23   0.94
  LA SR~a~, 1/s         −0.05            0.28             0.99   −0.12   0.27   0.97

CMR indicates cardiac magnetic resonance; EF, emptying fraction; ICC, intraclass correlation coefficient; LA, left atrial; S~max~, maximum strain; S~preA~, pre‐atrial contraction strain; SR~a~, strain rate at atrial contraction; SR~e~, strain rate at LV early diastole; SR~s~, maximum strain rate; V~max~, maximum indexed volume; V~min~, minimum indexed volume; V~preA~, pre‐atrial contraction indexed volume.

Discussion
==========

Main Findings
-------------

We found that greater LA volumes, lower LA EFs, lower strain, and lower peak SR were associated with a prior history of stroke. We also found that LA total EF, LA S~max~, and SR~s~, representing the LA reservoir function, are independently associated with stroke or TIA after adjusting for potential confounders and clinical risk factors. These results are consistent with the previous reports that the reduced LA reservoir function assessed using transthoracic echocardiography in the absence of AF is an independent predictor of clinical stroke/TIA^[@b4]^ as well as subclinical cerebrovascular events detected by brain MRI.^[@b5]^ Our findings are particularly important because, to our knowledge, this is the first report to demonstrate the significant contribution of the LA reservoir function to stroke in AF patients *during sinus rhythm*. In contrast to studies that showed a significant association between stroke and the LA reservoir function with echocardiography *during AF,*^[@b7]--[@b8]^ the sinus rhythm in our study allowed us to assess all the LA function components, including the reservoir function, conduit function, and booster pump function, and to successfully determine that only the LA reservoir function is significantly associated with stroke. This important finding further supports the concept that the underlying atrial fibrosis and subsequent LA dysfunction is mechanistically contributing to cerebrovascular events in AF patients.

Depressed LA Reservoir Function as a Mechanism of Thromboembolic Events in AF Patients
--------------------------------------------------------------------------------------

The atrial function consists of 3 components: a reservoir function for pulmonary venous return during LV systole, the conduit function for pulmonary venous return during LV early diastole, and the booster pump function that augments LV filling during LV late diastole ([Figure 3](#fig03){ref-type="fig"}). LA total EF, S~max~, and SR~s~ represent LA compliance and reservoir function, reflecting the passive stretch of the LA during LV systole. The mechanism as to how the depressed LA reservoir function leads to thromboembolic events is unclear. It is possible that the depressed LA reservoir function results in blood flow stasis in the LA and subsequent thrombus formation. Studies have also shown that low LA strains are associated with low flow velocities and thrombi in the LA appendage,^[@b20]^ which is the most common site of intracardiac thrombus.^[@b21]^ Of note, since none of the LV indices---mass, ejection fraction, end‐diastolic volume, and longitudinal strain---were significantly associated with stroke/TIA, the role of the LA reservoir function in the pathogenesis of intracardiac thrombosis is not due to the indirect consequence of LV function. The possibility that cardioversion‐induced atrial stunning could have confounded our findings is low because (1) cardioversion was performed in only a minority of patients in both groups; (2) there was no significant difference in the fraction of patients who underwent cardioversion between both groups; and (3) CMR was performed ≈8 weeks after cardioversion on average, while cardioversion‐induced atrial stunning usually recovers within 4 weeks.^[@b22]^ In our data set, there was no significant difference in the extent of the LA fibrosis quantified by LGE MRI between the stroke group and the control group. This finding is not consistent with a previous report,^[@b23]^ but this may be due to a small sample size since only a small number of patients underwent LGE (85 out of 169 patients).

LA Measurements by Tissue‐Tracking CMR
--------------------------------------

CMR has been established as a highly accurate and reproducible imaging modality, and is considered a standard clinical technique for measuring LA dimensions and volumes.^[@b24]--[@b25]^ We analyzed LA volume and function with tissue‐tracking CMR, which has been used to measure multiple LA parameters with excellent intra‐ and interobserver reproducibility in healthy subjects.^[@b10]--[@b11]^ Consistent with these previous reports, our results showed excellent inter‐ and intraobserver reproducibility for LA strain analysis with tissue‐tracking CMR, which is similar or superior to those of speckle‐tracking echocardiography^[@b26]^ Additionally, tissue‐tracking CMR can be performed with a routine cine CMR examination and does not require separate image acquisitions (eg, tagged MRI or displacement encoding with stimulated echoes (DENSE)^[@b27]^) or contrast media, although contrast media might be used in clinical settings to identify LA wall fibrosis in LGE and LA appendage thrombus as a sign of possible impending stroke in CMR angiography before AF ablations.^[@b28]^ Another strength of tissue‐tracking CMR is that it is user friendly. The images can be analyzed within minutes per patient by an operator without prior experience in image analysis, in contrast to LA fibrosis quantification with LGE that require hours of analysis per patient in the hands of an expert.

Clinical Implications
---------------------

The CHADS~2~ and CHA~2~DS~2~‐VASc scores are the most widely accepted and validated models to estimate the risk of stroke in AF patients.^[@b13]--[@b14]^ In addition, an increased LA volume is also associated with a higher risk of stroke.^[@b29]^ Our results demonstrate that the LA reservoir function is significantly associated with a prior history of stroke/TIA independent of the CHA~2~DS~2~‐VASc score and the LA volume ([Table 3](#tbl03){ref-type="table"}). Our results offer a basis for a prospective study to determine the role of LA reservoir function by tissue‐tracking CMR in predicting stroke or TIA. This may improve the current risk stratification strategy for stroke and potentially allow for early identification of subjects at risk of stroke, with or without a history of AF. Aggressive clinical management, such as early ablation or pharmacotherapy for AF to improve LA remodeling^[@b30]--[@b31]^ and early anticoagulation may reduce the risk of stroke in subjects with a high risk of stroke. In addition, further studies are warranted to investigate whether the risk of stroke decreases if LA function improves by these therapies.

Study Limitations
-----------------

This study represents a single‐center, retrospective, cross‐sectional analysis. Therefore, there is a non‐negligible chance of selection bias. For example, the analysis may be missing patients who died of stroke. In addition, CMR was not performed at the time of stroke/TIA, and the time from stroke to CMR could not be determined from the records. When evaluating the predictive value of the LA parameters for stroke, baseline LA strain analysis should ideally be assessed before stroke. Moreover, the stroke mechanism in each patient is unclear from the records. For the deformation analysis, we used only 2‐ and 4‐chamber cine CMR, which was included in a routine image‐acquisition protocol. Therefore, it is possible that our analysis underestimated the degree of dysfunction by missing regional dysfunction that was not covered by those 2 views. Since the strain was 2‐D and was obtained only in the in‐plane direction, the strain values may have been underestimated compared with those in 3‐D strains. In addition, the endo‐ and epicardial contours included the ostium of pulmonary veins and the LA appendage in a small number of patients. This could have led to underestimation of strain values; however, 2 previous studies used the same approach and validated the results.^[@b10]--[@b11]^ Despite these potential causes of underestimation, our analysis demonstrated a significant association between LA dysfunction and a prior history of stroke with excellent reproducibility ([Table 4](#tbl04){ref-type="table"}). Therefore, we believe that the advantage of our approach outweighs the disadvantage of including more views (eg, multiple short‐axis LA slices) and of excluding the ostia area to assess the whole LA deformation, which would increase the scan time and postprocessing burden.

Conclusions
===========

CMR measurements indicate that lower LA total EF, S~max~, and SR~s~, representing LA reservoir function, are significantly associated with a prior history of stroke/TIA in patients with AF. Our results offer a basis for a prospective study to determine the role of depressed LA reservoir function by tissue‐tracking CMR in predicting stroke or TIA for early detection of the population at risk of developing stroke.
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